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The serum level of IL-12 and IFN-g was also detected by
ELISA.
Results: Results of this study demonstrated that, 352
(9.5%) out of 3700 blood samples were HBsAg-/anti-HBc+
and HBV-DNA was detected in 57/352 (16.1%) of HBsAg-
/anti-HBc+ samples. Our results showed that groups showed
signiﬁcant difference in CC allele of +1188 region of IL-
12 and no difference was observed in the other evaluated
genes. Our results also showed that the alleles of +1188
region of IL-12 and alleles of +874 of IFN-g were also not
associated with serum level of cytokines.
Conclusion: According to the results of this study it may
be concluded that the polymorphisms in +1188 region of IL-
12 and +874 region of IFN-g would not affect the expression
of both cytokines at serum level in OBI patients.
doi:10.1016/j.ijid.2010.02.1987
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Occult hepatitis B virus infection in ART-naive HIV-
infected Indian patients
S. Singh
All India Institute of Medical Sciences, New Delhi, India
Background: Hepatitis viruses are frequently found as a
co-infection with HIV due to shared routes of transmission.
Globally the most common method of diagnosis is serology,
which can only detect active HBV infection while the occult
HBV infection may be missed. We estimated the burden of
HBV infection in patients who were tested positive for HIV
at a tertiary care centre in north India. We also attempted
to determine the prevalence and clinical characteristics of
occult HBV among these treatment-naïve patients and com-
pare their demographics features with other HIV patients.
Methods: During a period of 6 years between January
2002 to December 2007 837 HIV positive patients were
tested for serological markers of HBV (HBsAg) and HCV IgM
in our laboratory. For comparison 428 apparently healthy,
HIV-negative organ donors were also included in the study.
Data on demographics, sexual behaviour, medical history,
laboratory tests viz., serum ALT and CD4 count of these
patients were recorded. A sub-group of 53 HBsAg negative
samples from HIV positive patients were randomly selected
and assessed for anti-HBs, anti-HBc total (IgG+IgM) and HBV-
DNA using a highly sensitive qualitative PCR and analysed
retrospectively.
Results: Overall, 7.3% of HIV positive patients showed
presence of HBsAg as compared to 1.4% in the HIV negative
control group. The prevalence was higher (8.55%) in males
than females (3.39%). Overall occult HBV with detectable
HBV-DNA was found in 37.5% patients; being 45.5% in anti-
HBs positive patients and 30.7% in patients positive for anti-
HBc antibodies alone.
Conclusion: High prevalence of HIV-HBV co-infection was
found in our patients. The most reliable method to diagnose
occult HBV co-infection in HIV seropositive patients is the
detection of HBV DNA.
doi:10.1016/j.ijid.2010.02.1988
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reatment of chronic hepatitis C: The efﬁcacy and pre-
ictors of response to therapy
. Bozic
Institute for Infectious and Tropic Diseases, Belgrade, SER-
IA, Serbia
Background: The current standard for therapy of chronic
epatitis C (CHC) is combination of pegylated interferon
lpha (PEG IFN-&2a or PEG IFN-&2b) and ribavirin (RBV). It
s universally accepted that achievement of Sustained Viro-
ogical Response (SVR) means successful treatment. Certain
actors are good predictors of treatment outcome and they
rovide optimal, individual therapeutic approach.
Objectives: Evaluation of efﬁcacy of CHC treatment and
redictors of treatment response.
Methods: 194 patients with CHC were treated with
ombination therapy (PEG IFN-&2a + RBV).Virological exam-
nations: anti-HCV antibodies (ELISA), serum HCV RNK levels
nd HCV genotypes (PCR technique). Liver biopsy specimens
ere staged in accordance with the Metavir score. Predic-
or with inﬂuence on treatment outcome were estimated by
ultivariable logistic regression analysis.
Results: There were more patients of male gender
59.3%), older then 40 years (58.2%), with high basal HCV-
NA level (> 800.000 IU/ml, 63%), with G1 HCV (67%) in
reated group of patients with CHC. Bridging ﬁbrosis and cir-
hosis (F3, F4) were found in 54 (27.8%) of patients. SVR was
chieved in 69.2%, relapse was found in 11.9% of patients.
9.8% of patients had no response on therapy. Predictors for
chievement of SVR were: non-1 HCV genotype p = 0.002,
R 5.9 95% CI (1.9—18.0), achievement of early virologi-
al response (EVR) p = 0.000, OR 0.92, 95% CI (2.73—35.97),
nd patients younger the 40 years p = 0.005, OR 3.66 95% CI
1.48-9.0). Predictors for failure of therapy for patients who
idn’t respond to treatment were: G1 HCV p = 0.005, OR 3.9,
5 CI (1.5—10.3), high basal viral load p = 0.013, OR 3.45,
5% CI (1.29—9.19) and interupted continuity of treatment
= 0.002, OR 4.49, 95% CI (1.72—11.76).
Conclusion: The current standard antiviral therapy was
fﬁcient in 127/194 (69.2%) of our patients. The most impor-
ant predictors for successful treatment (SVR) were: non-1
CV genotype, achievement of EVR for G1 HCV and patients
ge. Predictors for failure of treatment were: G1 HCV, high
asal viral load, older age (>40 years), presence of cirrhosis
nd discontinuity of treatment.
oi:10.1016/j.ijid.2010.02.1989
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ccult hepatitis C virus infection among chronic liver dis-
ase patients in the United Arab Emirates
. Al-Moslih
University of Sharjah, P.O.Box 27272, Sharjah, United Arab
miratesBackground: Viral Hepatitis C (HCV) is one of the major
orld wide health problems. WHO estimates that about 3%
f the world’s population has been infected with HCV and
hat some 170 million are chronic carriers at risk of develop-
